XLO: Xilio Therapeutics Inc Company Profile & Statistics

About

Xilio Therapeutics Inc. is a biotechnology company which focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company's product candidate includes XTX101, XTX202, XTX301 and XTX401 which are in clinical stage. Xilio Therapeutics Inc. is based in WALTHAM, Mass.

Info & Links

CEO

Ren¿ Russo

Headquarters

828 Winter Street, Suite 300
Waltham, MA 02451, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

Xilio Therapeutics Inc Statistics

Valuation Measures

Market Capitalization²

37.18M

Enterprise Value

-24.08M

Enterprise Value/EBITDA(ttm)

0.38

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

2.03

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

Profit Margin(ttm)

-302.58%

Return on Equity(ttm)

-211.50%

Return on Invested Capital(ttm)

-223.23%

Return on Assets(ttm)

-80.31%

Income Statement

Revenue(ttm)

4.62M

Revenue Per Share(ttm)

0.11

Gross Profit(ttm)

4.62M

EBITDA(ttm)³

-63.36M

Net Income Available to Common(ttm)

-62.80M

Diluted EPS(ttm)

-1.72

Share Statistics

Beta (5Y Monthly)

-0.29

52-Week Change

-8.07%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

43.96M

Dividend Yield

0.00%

Float⁴

41.67M

% Held by Insiders

5.20%

% Held by Institutions

54.29%

Balance Sheet

Total Cash(mrq)

61.26M

Total Cash Per Share(mrq)

1.39

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

1.67%

Quick Ratio(mrq)

1.67%

Book Value Per Share(mrq)

0.48

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.07

Free Cash Flow(ytd)

-4.25M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

XLO

Xilio Therapeutics Inc

Xilio Therapeutics Inc Profile